Skip to main content
. 2021 Sep 24;38(11):5501–5518. doi: 10.1007/s12325-021-01884-7

Fig. 1.

Fig. 1

PRISMA diagram. aThe scope of the SLR was wider than the inclusion criteria of the DREAMM-2 study in order to provide an overview of the treatment landscape. bKey comparators to belantamab mafodotin included the following treatments administered as mono- or combination therapies: bortezomib, carfilzomib, daratumumab, dexamethasone, elotuzumab, ixazomib, lenalidomide, pomalidomide, and selinexor. PI, proteasome inhibitor; RRMM, relapsed or refractory multiple myeloma; SLR, systematic literature review; ITC, indirect treatment comparisons